Dr. Michael B. Jacobs, M.D., PH.D.
Internal Medicine (Internal Medicine Physician)
3017 W Charleston Blvd, Suite 60
Las Vegas, NV 89102
Who else practices at this address →
Clark County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Toledo College of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 165
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of Toledo College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
NV license 9037 · NY license 243291
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 165
- Services billed
- 747
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 415 | 150 |
| Established patient office or other outpatient visit, 20-29 minutes | 218 | 106 |
| Annual depression screening, 5 to 15 minutes | 91 | 91 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 89 | 89 |
| Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | 49 | 12 |
| New patient office or other outpatient visit, 45-59 minutes | 32 | 32 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 27 | 23 |
| Injection of trigger points, 1-2 muscles | 23 | 20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Las Vegas, NV | 273 |
| Levothyroxine Sodium Other prescribers in Las Vegas, NV | 145 |
| Rosuvastatin Calcium Other prescribers in Las Vegas, NV | 133 |
| Tamsulosin Hcl Other prescribers in Las Vegas, NV | 109 |
| Amlodipine Besylate Other prescribers in Las Vegas, NV | 103 |
| Metformin Hcl Other prescribers in Las Vegas, NV | 101 |
| Losartan-Hydrochlorothiazide (losartan/hydrochlorothiazide) Other prescribers in Las Vegas, NV | 98 |
| Furosemide Other prescribers in Las Vegas, NV | 81 |
| Metoprolol Succinate Other prescribers in Las Vegas, NV | 81 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Las Vegas, NV | 75 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 10 payments worth $223 in total to this clinician.
| Amgen Inc. | $53.63 |
|---|---|
| Baxter Healthcare | $43.33 |
| Acadia Pharmaceuticals Inc | $41.53 |
| Exact Sciences Corporation | $32.25 |
| Philips North America LLC | $20.05 |
| Lilly USA, LLC | $17.34 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.11 |
| Food and Beverage | $223 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 25 industry-funded studies in 2025, from 17 companies. The companies reported $1,270,683 in research payments for these studies, mostly to the institutions running them.
- A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Sanofi Pasteur Inc. · Completed · NCT06744205 - A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA
AstraZeneca Pharmaceuticals LP - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)
Alnylam Pharmaceuticals Inc. - A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine,…
Merck Sharp & Dohme LLC - BNT165-02
BioNTech SE - A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight…
AstraZeneca UK Limited - EBSI-CV-317-008
Bavarian Nordic A/s
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.